BioSpace News Archive

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the company will be presenting at the 2021 ICR Conference on Thursday, January 14, 2021 at 2:30 p.m. Eastern Standard Time. The Company will be represented at the conference by Jed Latkin, Chief Executive Officer, and J

SmilePartners-USA, a portfolio company of Silver Oak Services Partners, LLC, announced the acquisition of PEDIA, a leading provider of general dentistry and oral surgery services in Chicago, IL, operating 14 locations throughout the Chicago metropolitan area.

eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors for the treatment of cancer, announced that it has appointed Mike Byrnes as chief financial officer.

T2 Biosystems, Inc. (NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, today announced that its Board of Directors has appointed Aparna Ahuja, MD, as Chief Medical Officer (CMO), effective immediately.

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, January 14, 2021 at 4:30 p.m. Eastern Time. A live audio webcast of the corporate presentation and question and answer ses

Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX: VMD.TO and NASDAQ:VMD), a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced a recently completed non-invasive ventilation study led by Dr. William Frazier, Viemed’s Chief Medical Officer.

Global Blood Therapeutics, Inc. announced that on January 1, 2021, the compensation committee of GBT’s board of directors granted six new employees restricted stock units for an aggregate of 27,500 shares of the company’s common stock.

NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the appointment of Ronald McClurg, an experienced senior financial industry executive, as Chief Financial Officer of NeuroOne Medical Technologies Corporation

BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today announced the appointment of experienced biotechnology leader Robert F. Williamson, III as President and Chief Executive Officer and a member of the BioTheryX Board of Directors.

Ambrx Inc. today announced the appointment of Gary Yeung, CFA, MBA, as Chief Financial Officer and Chief Operating Officer. Mr. Yeung brings extensive leadership experience in raising capital, building biotech companies, and leading organizations to develop novel therapeutics